

# 1    **Original Article**

## 2    **Title**

3    Adherence to methotrexate and associated factors considering social desirability in patients  
4    with rheumatoid arthritis: a multicenter cross-sectional study

5

## 6    **Authors**

7    Nobuyuki Yajima, MD, MPH, PhD<sup>1,2,3</sup>; Takashi Kawaguchi, PhD<sup>4</sup>; Ryo Takahashi, MD<sup>1</sup>;  
8    Hiroki Nishiwaki, MD, MPH, PhD<sup>5,6</sup>; Yoichi Toyoshima, MD, PhD (ORCID ID,  
9    0000-0002-6097-2552)<sup>7</sup>; Koei Oh, MD, PhD<sup>8</sup>; Tsuyoshi Odai, MD, PhD<sup>9,10</sup>; Takayuki Kanai,  
10    MD, PhD<sup>11</sup>; Donald E. Morisky, ScD, MSPH<sup>12</sup>; Takuhiro Yamaguchi, PhD<sup>13</sup>; Tsuyoshi  
11    Kasama, MD, PhD (ORCID ID, 0000-0002-3871-6456)<sup>1</sup>

## 12    **Affiliations**

13    <sup>1</sup> Division of Rheumatology, Department of Medicine, Showa University School of Medicine,  
14    Tokyo, Japan

15    <sup>2</sup> Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine  
16    and Public Health, Kyoto, Japan

17    <sup>3</sup> Center for Innovative Research for Communities and Clinical Excellence, Fukushima

18 Medical University, Fukushima, Japan

19 <sup>4</sup> Department of Practical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy

20 and Life Sciences, Tokyo, Japan

21 <sup>5</sup> Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka

22 Hospital, Yokohama, Japan

23 <sup>6</sup> Showa University Research Administration Center, Tokyo, Japan

24 <sup>7</sup> Department of Orthopedic Surgery, Showa University Toyosu Hospital, Tokyo, Japan

25 <sup>8</sup> Department of Orthopedic Surgery, Showa University Northern Yokohama Hospital,

26 Yokohama, Japan

27 <sup>9</sup> Department of Internal Medicine, Showa University Northern Yokohama Hospital,

28 Yokohama, Japan

29 <sup>10</sup> Department of Rheumatology, Yokohama Asahi Central General Hospital, Kanagawa,

30 Japan.

31 <sup>11</sup> Department of Nephrology, Kanto Rosai Hospital, Kawasaki, Japan

32 <sup>12</sup> Department of Community Health Sciences, UCLA Fielding School of Public Health

33 <sup>13</sup> Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan

34 **Corresponding author:**

35 Nobuyuki Yajima

36 Division of Rheumatology, Department of Medicine, Showa University School of Medicine,

37 Tokyo, Japan

38 Address: 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan

39 Phone: +81-3-3784-8942; Fax: +81-3-3784-8946

40 E-mail: n.yajima@med.showa-u.ac.jp

41 ORCID iD: 0000-0002-8292-3962

42

## 43 **Abstract**

44 **Background:** Assessing medication adherence in rheumatoid arthritis (RA) is clinically  
 45 significant as low adherence is associated with high disease activity. Self-reported medication  
 46 adherence surveys have been shown to have problems with overestimation of adherence due  
 47 to social desirability bias. However, no MTX adherence studies adjusted for social  
 48 desirability have been conducted to date. This study aimed to evaluate adherence to MTX and  
 49 perform an investigatory search for factors associated with MTX adherence including social  
 50 desirability.

51 **Methods:** This cross-sectional multicenter study was conducted among adult RA patients

52 consuming oral MTX for  $\geq 3$  months. We examined the distribution of MTX adherence,  
53 according to the eight-item Morisky Medication Adherence Scale (MMAS-8). Furthermore,  
54 an exploratory factor analysis involving social desirability was examined to identify factors  
55 associated with MTX adherence using linear regression analysis. To deal with missing values,  
56 we used multiple imputations with chained equations methods.

57 **Results:** A total of 165 RA patients were enrolled. The median age was 64 years, and 86.1%  
58 were women. Based on the MMAS-8, low, medium, and high adherences were noted in  
59 12.1%, 60.0%, and 27.9% of participants, respectively. High social desirability (coefficient,  
60 0.14; 95% confidence interval [CI], 0.05–0.23;  $p < 0.05$ ) and high age (coefficient per 10 years,  
61 0.16; 95% CI, 0.01–0.03;  $p < 0.05$ ) were associated with high MTX adherence, whereas  
62 full-time work was negatively associated with high MTX adherence (coefficient, -0.50; 95%  
63 CI, -0.95–-0.05;  $p < 0.05$ ).

64 **Conclusions:** Sixty percent of RA patients had medium adherence to MTX. High social  
65 desirability, high educational level, and non-full-time work may be associated with high  
66 MTX adherence. Physicians should confirm MTX adherence before switching or adding  
67 disease-modifying anti-rheumatic drugs in cases of uncontrolled disease activity.

68 **Keywords:** rheumatoid arthritis, methotrexate, drug monitoring

69

## 70 **Background**

71 Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic  
72 inflammation. RA affects the joints and leads to functional disability in the absence of  
73 appropriate treatment [1]. The 2015 American College of Rheumatology (ACR) and the  
74 2019 European League against Rheumatism recommendations suggested the early use  
75 of disease-modifying antirheumatic-drugs (DMARDs), usually methotrexate (MTX), in  
76 most active RA patients [2,3]. Several studies have reported that low medication  
77 adherence is associated with high RA disease activity [4,5]. Hence, MTX adherence in  
78 RA patients is crucial.

79 Several studies on adherence to MTX have been conducted. However, MTX adherence  
80 differed among the studies because of the various definitions of adherence, different  
81 follow-up durations, and heterogeneity of patient populations. A previous study reported  
82 that MTX adherence is associated with age, sex, race, RA disease activity, patient  
83 beliefs about the medication, disease duration, mental health, and socio-economic status  
84 (SES) [4,6–10]. In a systematic review, beliefs on the necessity and efficacy of MTX,  
85 absence of low mood, mild disease, and MTX monotherapy were identified as the most  
86 reliable variables related to MTX adherence [11].

87 Social desirability is well known to influence the use of self-reported questionnaires in  
 88 research. A previous study reported that social desirability is the tendency to respond to  
 89 self-reported items in a way that reflects better on the respondent rather than acting  
 90 accurately and truthfully [12]. Self-reported medication adherence surveys have been  
 91 shown to have problems with overestimation of adherence due to social desirability bias  
 92 [13,14]. A previous MTX adherence study has reported the need to control this bias  
 93 [15]; however, no studies have investigated the MTX adherence survey by controlling  
 94 for social desirability. Thus, this study aimed to evaluate the adherence of RA patients to  
 95 MTX and exploratively evaluate factors associated with MTX adherence with the  
 96 addition of social desirability.

## 97 **Methods**

### 98 *Study design*

99 This cross-sectional study was conducted in four hospitals: Showa University Hospital,  
 100 Showa University Northern Yokohama Hospital, Showa University Fujigaoka Hospital,  
 101 and Kanto Rosai Hospital.

### 102 *Patient population*

103 Participants were outpatients who met the 2010 ACR criteria for RA [16]. The  
104 inclusion criteria were age  $\geq 20$  years and consumption of oral MTX for  $\geq 3$  months. The  
105 exclusion criteria were patients with dementia, restlessness, and severe psychiatric  
106 disorders. Sequential sampling was employed. Patients were recruited between August  
107 2013 and October 2014.

# 108 ***Data collection***

109 RA disease activity was assessed using the Disease Activity Score in 28 joints  
110 (DAS28-ESR). DAS28 provides a global summative and continuous score for disease  
111 activity assessment and has been widely used in clinical trials and practice [17].  
112 Activities of daily living (ADL) was assessed using the modified Health Assessment  
113 Questionnaire (mHAQ), which is a self-reported questionnaire that measures function,  
114 including ADL performance. Depression state was defined using the Centre for  
115 Epidemiological Studies-Depression (CES-D) scale, which includes a 20-item  
116 questionnaire; the scores range from 0 to 60. We determined that a total score of  $\geq 16$   
117 describes a depressive state [18]. The patient's perceptions towards medications were  
118 assessed using the Belief about Medicines Questionnaire-Specific (BMQ-specific),

119 which includes two domains, BMQ-Specific necessity (5 items) and BMQ-Specific  
120 concern (5 items). The responses are recorded on a 5-point Likert Scale (ranging from  
121 1=strongly disagree to 5=strongly agree). The score by domains ranges from 5 to 25;  
122 higher scores indicate stronger beliefs in the concepts represented by the scale. We used  
123 the BMQ necessity-concern differential (“BMQ-Specific necessity” minus  
124 “BMQ-Specific concern”) which shows appropriate reliability and was used in  
125 numerous studies in multivariable analysis [19]. Pain severity was assessed using the  
126 Brief Pain Inventory (BPI). Moreover, we measured the following: worst numerical  
127 rating scale (NRS) pain score, least NRS pain score, average NRS pain score, and  
128 current NRS pain score. We used the average NRS pain score other clinical studies have  
129 applied in the multivariable analysis. Social desirability is typically assessed using the  
130 Social Desirability Scale (SDS) developed by Crowne and Marlowe in 1960, with 33  
131 items [20]. Furthermore, a 13-item SDS was developed with confirmed validity and  
132 reliability [21]. In this study, we used the 13-item SDS. Short Form-8 (SF-8) is a  
133 health-related quality of life (QoL) questionnaire, which measures the same eight health  
134 domains (physical functioning, role physical, bodily pain, general health, vitality, social



135 functioning, role emotional, and mental health) similar to Short Form-36 (SF-36v2®)

136 but shorter, using eight questions and whose validity and reliability were confirmed [22].

137 This questionnaire was used to assess the QoL in RA [23]. The score range of each

138 domain is from 0 to 100; higher scores suggest better health-related QoL. We used two

139 summary scores: mental component summary (MCS; showing mental status) and

140 physical component summary (PCS; showing physical status). The Japanese versions of

141 mHAQ, CES-D, BMQ, BPI, SDS, and SF-8 were validated [24,25].

142 Additionally, we obtained data on SES, including marital status, educational level,

143 employment status, and living status. Data on patient characteristics, medication, and

144 SES were further collected using questionnaires. Other data were obtained from medical

145 chart records. After consulting the doctor, the participants answered the Morisky

146 Medication Adherence Scale (MMAS-8), mHAQ, CES-D, BMQ, BPI, SDS, SF-8, and

147 SES questionnaires; they returned the completed questionnaires to the data center by

148 mail.

# 149 ***Outcome***

150 The primary outcome was the distribution of MTX adherence according to MMAS-8

151 at the time of the survey based on the patient's description. MMAS-8 consists of an  
152 eight-item questionnaire [26–28]. MMAS-8 scores range from 0 to 8 and are classified  
153 as follows: low, <6; medium, >6 and <8; and high, 8. Originally, MMAS-8 was  
154 developed for daily administration of oral medicine. MTX was administered once a  
155 week; thus, we developed the Japanese questionnaire for MTX accordingly. First, we  
156 translated the questionnaire from English to Japanese and resolved some language  
157 discrepancies. Second, back translations were performed. Third, we discussed the  
158 questionnaire and achieved a consensus. Finally, a pre-test in five RA patients followed  
159 by necessary modifications were performed to finalize the Japanese questionnaire.

#### 160 *Statistical analyses*

161 MMAS-8, sex, CES-D, and SES were used as categorical variables, whereas age,  
162 MTX dose, MTX dosing frequency, duration of MTX treatment, disease duration,  
163 DAS28-ESR, mHAQ, BMQ, BPI, SDS, and SF-8 were used as continuous variables.  
164 Summary statistics were presented as median with interquartile range (IQR) and  
165 numbers with proportion (%). First, we evaluated the distribution of MTX adherence  
166 according to MMAS-8. Subsequently, we compared MMAS-8 and pre-described factors

167 using one-way analysis of variance (ANOVA), Kruskal-Wallis test, and chi-squared test.

168 For significant factors, we conducted a trend analysis. Finally, multiple linear regression

169 analysis was performed to exploratively assess factors associated with MTX adherence

170 with the addition of social desirability. The co-variables selected were as follows: age,

171 sex, disease duration, RA disease activity (DAS28-ESR), depression state (CES-D),

172 reliability of the medication (BMQ necessity-concern differential), social desirability

173 (SDS), educational level (more than, equal to college-level, or not), and employment

174 status (full-time work or not). These factors were further selected based on previous

175 studies and clinical importance [4,6–10,29–31].

176 This was an observational study; hence, the sample size was not calculated on a

177 statistical basis but was measured to the extent practicable over the study period. To

178 compare the mean DAS-28 scores among the three groups using ANOVA, the effect

179 size (small, 0.1; medium, 0.25; and large: 0.4) customarily proposed by Cohen [32] was

180 set at medium (0.25), the significance level was set at 5% on both sides, and the power

181 was set at 80%. The total number of cases was calculated to be 159. The target number

182 of cases was 176, assuming a dropout rate of 10%.

183 To deal with missing values, we used multivariable multiple imputations with chained  
 184 equations methods to increase power and minimize selection bias. We included age, sex,  
 185 disease duration, RA disease activity, depression state, reliability of the medication,  
 186 social desirability, educational level, and employment status for each imputation model.  
 187 We generated 10 imputed datasets and combined coefficient estimates using Rubin's  
 188 rules for each imputation. Imputation of missing data in this way assumes that data were  
 189 missing at random since any reasons for missing were explained by the observed  
 190 variables included in the imputation model.

191 A two-sided p-value <0.05 was considered statistically significant. All statistical  
 192 analyses were conducted using STATA 14.2 (StataCorp LP, College Station, TX)  
 193 software.

#### 194 ***Ethical considerations***

195 The ethics committee of Showa University Hospital (approval number 1446) and  
 196 Showa University Toyosu Hospital, Showa University Northern Yokohama Hospital,  
 197 Kanto Rosai Hospital approved this study, and informed consent was obtained from all  
 198 participants before study enrolment. All study procedures were performed in accordance

199 with the Declaration of Helsinki. Patient information was anonymized and de-identified  
200 before analysis.

## 201 **Results**

### 202 ***Patient flow chart***

203 Figure 1 shows the patient flow chart. Initially, 181 RA patients were invited. Of 169  
204 patients eligible for the study, four were excluded because of missing MTX adherence  
205 data (n=2) and clinical data (n=2). A total of 165 RA patients were included in the final  
206 analysis.

### 207 ***Baseline characteristics***

208 The characteristics of the participants are shown in Table 1. The median age of the  
209 patients was 64 years (IQR, 54–72), and 86.1% were women. The median dose of MTX  
210 was 8 mg per week (IQR, 6–12), median MTX dosing frequency was three times per  
211 week (IQR, 2–3), and median duration of MTX treatment was 36 months (IQR, 17–75).  
212 The proportion of missing data varied from 0 to 15.2% (Supplementary table 1).

213 **INSERT TABLE 1 HERE**

### 214 ***Distribution of MTX adherence***

215 Based on MMAS-8, low, medium, and high adherence rates were noted in 12%  
216 (20/165), 60% (99/165), and 28% (46/165) of cases, respectively. The median MMAS-8  
217 score was 7 (IQR, 6.5–8).

### 218 *Patient's characteristics by grade of MTX adherence*

219 Patient's characteristics by grade of MTX adherence divided by MMAS-8 are shown  
220 in Table 1. A significant association between levels of MTX adherence and age, mHAQ,  
221 SDS, SF-8 (PCS), and employment status was found. Based on trend analysis, older  
222 participants had significantly high adherence, and the higher the social desirability, the  
223 higher the adherence. However, a significant association between MTX adherence and  
224 mHAQ and SF-8 (PCS) was not observed in the trend analysis.

### 225 *Factors associated with high MTX adherence considering social desirability*

226 In the multiple linear regression analysis adjusted for age, sex, disease duration, RA  
227 disease activity (DAS28-ESR), depression state (CES-D), reliability of the medication  
228 (BMQ necessity-concern differential), social desirability (SDS), educational level (more  
229 than or equal to college-level or not), and employment status (full-time work or not),  
230 higher social desirability (coefficient, 0.14; 95% confidence interval [CI], 0.05–0.23;

231 p<0.05) and higher age (coefficient per 10 years, 0.16; 95% CI, 0.01–0.03; p<0.05)  
232 were associated with high MTX adherence, whereas full-time work was negatively  
233 related to high MTX adherence (coefficient, -0.50; 95% CI, -0.95–0.05; p<0.05) (Table  
234 2).

235 **INSERT TABLE 2 HERE**

236

## 237 **Discussion**

238 Elderly participants and high social desirability were significantly associated with high  
239 adherence based on trend analysis. Multiple linear regression analysis showed that high  
240 MTX adherence in RA patients is associated with high social desirability, high  
241 educational level, and non-full-time work.

242 In our study, only 27.9% of the participants showed high medication adherence.  
243 Several studies reported that adherence to DMARDS was 40%–107% [9,33,34]. There  
244 are several potential reasons for the observed low adherence. First, the method of  
245 adherence measurement in each study was different. There were interviews,  
246 questionnaires, tablet count, drug concentration, and doctor's judgment as

247 measurements. A previous study showed that the adherence to interview, tablet count,  
248 drug concentration, and doctor's judgment were 96%, 77%, 58%, and 42%, respectively,  
249 which showed vast differences [35]. Since each measurement has advantages and  
250 disadvantages, the gold standard is not determined. We chose a self-reported  
251 questionnaire in this study since this scale is not expensive or invasive and can be  
252 possibly validated. Second, the time point of adherence measurement was different  
253 between the studies. We measured adherence during the maintenance period (mean  
254 disease duration, 53 months). A previous report suggested that the adherence of  
255 DMARDs in the early period was low (58%) [5]. Another study reported the adherence  
256 to salazosulfapyridine as 87% at three years from the start of medication [30]. In  
257 contrast, the adherence to DMARDs in the maintenance period varied from 84%,<sup>4</sup> 70%  
258 [36], to 95.4% [37]. Previous reports have suggested that the adherence to DMARDs  
259 was not different between the early and maintenance periods. It is crucial to note that  
260 the time point of measuring medication adherence is the maintenance period because  
261 RA is a chronic disease that requires DMARDs for a long duration. The third is the  
262 difference in participant characteristics. Living status and marital status affected



263 adherence [10,38]. Our study could not adjust the living status and marital status  
 264 because we could not include more factors based on our sample size. In addition, the  
 265 age of the participants may have had an effect. In the original MMAS-8 article [26], the  
 266 mean age was 52 years; however, in our study, the median age was 64 years, which  
 267 means that the participants in our study were older, and this may have influenced the  
 268 results. Furthermore, older people may not have revealed the truth. Thus, when referring  
 269 to drug adherence studies, the method of measuring adherence, whether the target  
 270 patient is in the disease's early or maintenance phase, and the patient's characteristics  
 271 should be confirmed before adaptation.

272 Our study detected high social desirability, high educational level, and non-full-time  
 273 work as factors affecting MTX adherence. A previous study reporting MTX adherence  
 274 found that adherence is associated with age, sex, race, RA disease activity, patient  
 275 beliefs about the medication, disease duration, mental health, and SES. The discrepancy  
 276 between our findings and those of other studies could be attributed to three reasons.  
 277 First, we measured and adjusted social desirability, which possibly affected the answers  
 278 in the questionnaire. Although a recent MTX adherence research mentioned the

279 necessity to account for this bias [15], no studies have examined how MTX adherence  
280 survey accounts for social desirability. The results may have differed since we  
281 conducted a factor search that included social desirability. Second, racial differences  
282 may have led to different outcomes. Our study was based on a Japanese population;  
283 however, previous studies were mainly on white people, black people, and Hispanic  
284 people. Canon et al. reported that the adherence to MTX was associated with the  
285 Caucasian race [4]. Therefore, adherence may be influenced by race. Third, the  
286 definition of medication adherence varies between studies. We used MMAS-8 in our  
287 study. Conversely, previous studies used other methods to assess medication adherence,  
288 such as physicians' estimation, different self-reported scales, drug concentration, tablet  
289 count electronic monitors, and other questionnaires. A prior study reported that  
290 medication adherence differs because the measurement method employed seems to vary  
291 [11]. Therefore, we need to practice caution when using research results because the  
292 results may differ depending on the method of measuring adherence and the variables  
293 incorporated, including social desirability.

294 Our study demonstrated that RA patients with high social desirability had high MTX

adherence. A previous study reported that social desirability refers to responding to self-reported items that make the respondent seem better [12]. Contrastingly, the influence of social desirability is unknown, although its significance is generally accepted. A previous report has suggested that social desirability does not play a major role in assessing subjective well-being [39]. Therefore, although the effect of social desirability on drug adherence may not be significant, we were able to search for factors that consider social desirability.

Our study had three strengths. First, we assessed social desirability, leading to social desirability bias. To our knowledge, no clinical studies adjusting social desirability have investigated the association between MTX adherence and various factors. Second, to our knowledge, this is the first research to examine MTX adherence in an Asian population. Third, the response rate to the questionnaires was high (93.4%), thereby strengthening internal validity.

This study has significant implications for the clinician. Our findings may prevent unnecessary DMARDs changes since physicians tend to overestimate patients' medication adherence [40]. They should confirm MTX adherence before switching or

311 adding DMARDS. Accordingly, this provides an opportunity to reduce the healthcare  
312 cost and adverse events of medication.

313 However, this study had several limitations. First, in the multivariable analysis, some  
314 immeasurable essential factors (such as characteristics of each participant, joint  
315 deformities, number of medications, and MTX dosing frequency) that could affect MTX  
316 adherence possibly exist. We did not determine patient personality due to the difficulty  
317 in quantifying it. In addition, we did not collect radiographs even if they are necessary  
318 for determining joint deformity because they are burdensome for patients. However, we  
319 adjusted for joint deformity using the mHAQ to reduce its possible influence on the  
320 findings. In addition, although the number of MTX doses was collected, it was not  
321 possible to incorporate variables due to sample size limitations. Second, the  
322 generalizability of our findings is limited. Our study setting was primarily university  
323 hospitals in Japan; thus, the results of this study cannot be applied to the clinical setting,  
324 in small- and medium-sized hospitals, or in settings including other races. Furthermore,  
325 the highest dose of MTX in Japan in the study was 8 mg per week. This dose is less  
326 than the standard dose of 20 mg worldwide, which limits the indications. Third, we used

327 a self-reported questionnaire of adherence. Hence, the completed questionnaire possibly  
328 influenced social desirability. Although we could not adjust this bias completely, social  
329 desirability was added as a factor for analysis.

## 330 **Conclusions**

331 Our results demonstrated that sixty percent of the RA patients had moderate adherence  
332 to MTX. Moreover, high MTX adherence in RA patients is associated with high social  
333 desirability, high educational level, and non-full-time work.

334

## 335 **List of Abbreviations**

336 ADL: Activities of Daily Living

337 BMQ: Beliefs about Medicines Questionnaire

338 BPI: Brief Pain Inventory

339 CES-D: Center for Epidemiological Studies Depression

340 DAS28-ESR: Disease Activity Score (28 joint count)-erythrocyte sedimentation rate

341 DMARDs: disease-modifying antirheumatic-drugs

342 MCS: mental component summary

343 mHAQ: modified Health Assessment Questionnaire

344 MMAS-8: Morisky Medication Adherence Scale

345 MTX: methotrexate

346 NRS: Numerical Rating Scale

347 PCS: physical component summary

348 RA: rheumatoid arthritis

349 SDS: Social Desirability Scale

350 SF-8: 8-item Short-Form Health Survey

351

## 352 **Declarations**

### 353 ***Ethics approval and consent to participate***

354 The ethics committee of Showa University Hospital (approval number 1446) and other

355 each institution approved this study, and informed consent was obtained from all

356 participants before study enrolment. All study procedures were performed in accordance

357 with the Declaration of Helsinki. Patient information was anonymized and de-identified

358 before analysis.

359 ***Consent for publication***

360 Not applicable.

361 ***Availability of data and materials***

362 The dataset analyzed in this paper is available from the corresponding author on  
363 reasonable request.

364

365 ***About MMAS8***

366 The use of the MMAS diagnostic adherence assessment instrument is protected by US  
367 copyrighted and trademarked laws. Permission for use is required. A license is available  
368 from MORISKY MEDICATION ADHERENCE RESEARCH, LLC., Donald E.  
369 Morisky, ScD, ScM, MSPH, MMAR, LLC, 294 Lindura Ct., Las Vegas, NV 89138;  
370 [dmorisky@gmail.com](mailto:dmorisky@gmail.com).

371

372 ***Competing interests***

373 Donald E. Morisky holds a copyright for the Morisky Medication Adherence Scale-8, is  
374 one of its authors, and collects fees in exchange for licenses to use the scale in research.

375 This does not alter the authors' commitment to objectivity in research or adherence to  
376 data sharing policies. He was not involved in any data analysis. For the remaining  
377 authors, none were declared.

### 378 ***Funding***

379 The authors have not received funding to conduct this study.

### 380 ***Authors' contributions***

381 Nobuyuki Yajima: Methodology, Project administration, Writing – original draft,

382 Writing – Review & Editing

383 Takashi Kawaguchi: Supervision, Conceptualization, Project Administration, Writing –

384 original draft, Writing – Review & Editing

385 Ryo Takahashi: Data curation, Writing – original draft, Writing – Review & Editing

386 Hiroki Nishiwaki: Data curation, Writing – original draft, Writing – Review & Editing

387 Youichi Toyoshima: Data curation, Writing – original draft, Writing – Review & Editing

388 Koei O: Data curation, Writing – original draft, Writing – Review & Editing

389 Tsuyoshi Odai: Data curation, Writing – original draft, Writing – Review & Editing

390 Takayuki Kanai: Data curation, Writing – original draft, Writing – Review & Editing



391 Donald E. Morisky: Supervision, Writing – original draft, Writing – Review & Editing

392 Takuhiro Yamaguchi: Formal Analysis, Supervision, Writing – original draft, Writing –

393 Review & Editing

394 Tsuyoshi Kasama: Supervision, Writing – original draft, Writing – Review & Editing

### 395 *Acknowledgments*

396 We thank Noboru Murata (Kikuna Memorial Hospital) and Osamu Namiki for critically

397 reviewing the manuscript.

398

### 399 *Authors' information*

400 **Division of Rheumatology, Department of Medicine, Showa University School of**

401 **Medicine, Tokyo, Japan**

402 Nobuyuki Yajima, Ryo Takahashi, Tsuyoshi Kasama

403 **Department of Healthcare Epidemiology, Kyoto University Graduate School of**

404 **Medicine and Public Health, Kyoto, Japan**

405 Nobuyuki Yajima

406 **Center for Innovative Research for Communities and Clinical Excellence,**  
 407 **Fukushima Medical University, Fukushima, Japan**

408 Nobuyuki Yajima

409 **Department of Practical Pharmacy, School of Pharmacy, Tokyo University of**  
 410 **Pharmacy and Life Sciences, Tokyo, Japan**

411 Takashi Kawaguchi

412 **Division of Nephrology, Department of Internal Medicine, Showa University**  
 413 **Fujigaoka Hospital, Yokohama, Japan**

414 Hiroki Nishiwaki

415 **Showa University Research Administration Center, Tokyo, Japan**

416 Hiroki Nishiwaki

417 **Department of Orthopedic Surgery, Showa University Toyosu Hospital, Tokyo,**  
 418 **Japan**

419 Yoichi Toyoshima

420 **Department of Orthopedic Surgery, Showa University Northern Yokohama**  
 421 **Hospital, Yokohama, Japan**

422 Koei Oh

423 **Department of Internal Medicine, Showa University Northern Yokohama Hospital,**

424 **Yokohama, Japan**

425 Tsuyoshi Odai

426 **Department of Rheumatology, Yokohama Asahi Central General Hospital,**

427 **Kanagawa, Japan.**

428 Tsuyoshi Odai

429 **Department of Nephrology, Kanto Rosai Hospital, Kawasaki, Japan**

430 Takayuki Kanai

431 **Department of Community Health Sciences, UCLA Fielding School of Public**

432 **Health**

433 Donald E. Morisky

434 **Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi,**

435 **Japan**

436 Takuhiro Yamaguchi

## 437     **References**

- 438     1.     van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof  
439     MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a  
440     three-year prospective followup of patients with early rheumatoid arthritis. Arthritis  
441     Rheum. 1992;35:26-34.
- 442     2.     Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al.  
443     2015 American College of Rheumatology Guideline for the treatment of rheumatoid  
444     arthritis. Arthritis Care Res (Hoboken). 2016;68:1-25.
- 445     3.     Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M,  
446     Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid  
447     arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019  
448     update. Ann Rheum Dis. 2020;79:685-99.
- 449     4.     Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, et al.  
450     Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess  
451     methotrexate adherence and disease activity in clinical practice. Arthritis Care Res  
452     (Hoboken). 2011;63:1680-90.

- 453 5. Contreras-Yanez I, Ponce De Leon S, Cabiedes J, Rull-Gabayet M,  
454 Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in  
455 patients with rheumatoid arthritis who have achieved remission with  
456 disease-modifying antirheumatic drugs. Am J Med Sci. 2010;340:282-90.
- 457 6. De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants  
458 of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol.  
459 2016;35:1335-9.
- 460 7. DiBenedetti DB, Zhou X, Reynolds M, Ogale S, Best JH. Assessing  
461 methotrexate adherence in rheumatoid arthritis: a cross-sectional survey. Rheumatol  
462 Ther. 2015;2:73-84.
- 463 8. Salt E, Frazier SK. Adherence to disease-modifying antirheumatic drugs in  
464 patients with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs.  
465 2010;29:260-75.
- 466 9. Scheiman-Elazary A, Duan L, Shourt C, Shourt C, Agrawal H, Ellashof D, et al.  
467 The rate of adherence to antiarthritis medications and associated factors among  
468 patients with rheumatoid arthritis: a systematic literature review and metaanalysis. J

- 469 Rheumatol. 2016;43:512-23.
- 470 10. Waimann CA, Marengo MF, de Achaval S, Cox VL, Garcia-Gonzalez A,  
471 Reveille JD, et al. Electronic monitoring of oral therapies in ethnically diverse and  
472 economically disadvantaged patients with rheumatoid arthritis: consequences of low  
473 adherence. Arthritis Rheum. 2013;65:1421-9.
- 474 11. Hope HF, Bluett J, Barton A, Hyrich KL, Cordingley L, Verstappen SM.  
475 Psychological factors predict adherence to methotrexate in rheumatoid arthritis;  
476 findings from a systematic review of rates, predictors and associations with  
477 patient-reported and clinical outcomes. RMD Open. 2016;2:e000171.
- 478 12. Holtgraves T. Social desirability and self-reports: testing models of socially  
479 desirable responding. Pers Soc Psychol Bull. 2004;30:161-72.
- 480 13. Hebel S, Kahn-Woods E, Malone-Thomas S, McNeese M, Thornton L,  
481 Sukhija-Cohen A, et al. Brief report: discrepancies between self-reported adherence  
482 and a biomarker of adherence in real-world settings. J Acquir Immune Defic Syndr.  
483 2020;85:454-7.
- 484 14. van der Straten A, Montgomery ET, Hartmann M, Minnis A. Methodological

485 lessons from clinical trials and the future of microbicide research. *Curr HIV/AIDS Rep.*  
486 2013;10:89-102.

487 15. Aaltonen KJ, Turunen JH, Sokka T, Puolakka K, Valleala H. A survey on the  
488 medication adherence to methotrexate among rheumatoid arthritis patients treated with  
489 self-administered biologic drugs. *Clin Exp Rheumatol.* 2016;34:694-7.

490 16. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3<sup>rd</sup>, et al.  
491 2010 rheumatoid arthritis classification criteria: an American College of  
492 Rheumatology/European League against Rheumatism collaborative initiative. *Arthritis*  
493 *Rheum.* 2010;62:2569-81.

494 17. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB,  
495 van Riel PL. Modified disease activity scores that include twenty-eight-joint counts.  
496 Development and validation in a prospective longitudinal study of patients with  
497 rheumatoid arthritis. *Arthritis Rheum.* 1995;38:44-8.

498 18. Radloff LS. The CES-D scale: a self-report depression scale for research in the  
499 general population. *Appl Psychol Meas.* 1977;1:385-401.

500 19. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role

501 in adherence to treatment in chronic physical illness. J Psychosom Res.

502 1999;47:555-67.

503 20. Crowne DP, Marlowe D. A new scale of social desirability independent of

504 psychopathology. J Consult Psychol. 1960;24:349-54.

505 21. Reynolds WM. Development of reliable and valid short forms of the

506 Marlowe-Crowne social desirability scale. J Clin Psych. 1982;38:119-25.

507 22. Ware JE, GlaxoSmithKline. How to score and interpret single-item health

508 status measures: a manual for users of the of the SF-8 health survey: (with a

509 supplement on the SF-8 health survey). Lincoln, RI; QualityMetric, Inc.; Boston, MA:

510 Health Assessment Lab. 2001.

511 23. Birrell FN, Hassell AB, Jones PW, Dawes PT. How does the short form 36

512 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome

513 measures and SF-36 population values? A cross-sectional study. Clin Rheumatol.

514 2000;19:195-9.

515 24. Iihara N, Suzuki K, Kurosaki Y, Morita S, Hori K. Factorial invariance of a

516 questionnaire assessing medication beliefs in Japanese non-adherent groups. Pharm



- 517 World Sci. 2010;32:432-9.
- 518 25. Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain  
519 assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory--BPI-J. J  
520 Pain Symptom Manage. 1998;16:364-73.
- 521 26. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a  
522 medication adherence measure in an outpatient setting. J Clin Hypertens. (Greenwich)  
523 2008;10:348-54.
- 524 27. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, et al.  
525 Effect of intensive blood-pressure treatment on patient-reported outcomes. N Engl J  
526 Med. 2017;377:733-44.
- 527 28. Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, et al.  
528 Cost-effectiveness of intensive versus standard blood pressure control. N Engl J Med.  
529 2017;377:745-55.
- 530 29. Lorish CD, Richards B, Brown S. Missed medication doses in rheumatic  
531 arthritis patients: intentional and unintentional reasons. Arthritis Care Res. 1989;2:3-9.
- 532 30. Brus HL, van de Laar MA, Taal E, Rasker JJ, Wiegman O. Effects of patient

533 education on compliance with basic treatment regimens and health in recent onset

534 active rheumatoid arthritis. *Ann Rheum Dis*. 1998;57:146-51.

535 31. Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T, van den Heuvel W.

536 Compliance with drug therapy in rheumatoid arthritis. A longitudinal European study.

537 *Joint Bone Spine*. 2000;67:178-82.

538 32. Cohen, J. A power primer. *Psychol Bull*. 1992;112:155-9.

539 33. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in

540 patients with rheumatoid arthritis: a critical appraisal of the existing literature. *Expert*

541 *Rev Clin Immunol*. 2012;8:337-51.

542 34. Curtis JR, Bykerk VP, Aassi M, Schiff M. Adherence and persistence with

543 methotrexate in rheumatoid arthritis: a systematic review. *J Rheumatol*.

544 2016;43:1997-2009.

545 35. Pullar T, Peaker S, Martin MF, Bird HA, Feely MP. The use of a

546 pharmacological indicator to investigate compliance in patients with a poor response to

547 antirheumatic therapy. *Br J Rheumatol*. 1988;27:381-4.

548 36. van den Bemt BJ, den Broeder AA, van den Hoogen FH, Benraad B, Hekster

549 YA, van Riel PL, et al. Making the rheumatologist aware of patients' non-adherence  
550 does not improve medication adherence in patients with rheumatoid arthritis. Scand J  
551 Rheumatol. 2011;40:192-6.

552 37. Park DC, Hertzog C, Leventhal H, Morrell RW, Leventhal E, Birchmore D, et  
553 al. Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr  
554 Soc. 1999;47:172-83.

555 38. De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants  
556 of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol.  
557 2016;35:1335-9.

558 39. McCrae RR. Well-being scales do not measure social desirability. J Gerontol.  
559 1986;41:390-2.

560 40. Gossec L, Molto A, Romand X, Puyraimond-Zemmour D, Lavielle M,  
561 Beauvais C, et al. Recommendations for the assessment and optimization of adherence  
562 to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process  
563 based on literature reviews and expert consensus. Joint Bone Spine. 2019;86:13-19.

565

566

567

568

569

570

571

572

573

574

## 575 **Figure Legend**

576 **Figure 1.** Patient flow chart

577

## 578 **Tables**

579 **Table 1. Patient characteristics by grade of MTX adherence divided by MMAS-8 (n=165)**

580

	All (n=165)	MMAS-8			p value
		Low (n=20)	Medium (n=99)	High (n=46)	
Age, median (IQR)	64	58	65	65.5	0.01

	(54–72)	(44–62)	(53–73)	(59–74)	
Female, n (%)	142 (86.1)	18 (90.0)	84 (84.6)	38 (82.6)	0.74
MTX dose (mg/week), median (IQR)	8 (6–12)	10 (8–12)	8 (6–10)	10 (8–12)	0.17
MTX dosing frequency (times/week), median (IQR)	3 (2–3)	3 (2–3)	2 (2–3)	2 (2–3)	0.54
Duration of MTX treatment (month), median (IQR)	36 (17–75)	32 (16–79)	35 (18–80)	41 (13–74)	0.15
Disease duration (month), median (IQR)	53.5 (22.5–123.5)	35 (22–120)	47 (22–111)	60.5 (24–158)	0.95
Concomitant medication					
NSAIDs, n (%)	59 (35.8)	5 (25.0)	36 (36.4)	8 (39.1)	0.53
Corticosteroid, n (%)	27 (16.4)	2 (10.0)	17 (17.2)	8 (17.4)	0.71
Biologics, n (%)	48 (29.1)	7 (35.0)	28 (28.3)	13 (28.3)	0.83
DAS28-ESR, median (IQR)	2.30 (1.68–3.00)	2.01 (1.37–2.23)	2.32 (1.68–3.02)	2.40 (2.01–3.15)	0.08
mHAQ, median (IQR)	0 (0–0.13)	0 (0–0.25)	0 (0–0)	0.13 (0–0.38)	0.02
BMQ necessity-concern differential, median (IQR)	1 (0–3)	2 (0–3)	1 (0–3)	2 (0–3)	0.81
CES-D (total score $\geq 16$ ), n (%)	37 (26.4)	8 (47.1)	21 (8.3)	8 (20.0)	0.10
BPI (average NRS pain score), median (IQR)	2 (1–3)	1 (1–4)	1 (1–3)	1 (3–4)	0.13
SDS, median (IQR)	6 (4–7)	4 (3–6)	6 (4–6)	6.5 (5–8)	0.00
SF-8 (PCS), median (IQR)	48.1 (42.4–52.1)	47.4 (45.8–52.1)	49.8 (43.5–52.1)	45.6 (40.2–50.2)	0.04
SF-8 (MCS), median (IQR)	50.2 (45.6–54.1)	47.7 (43.0–53.2)	50.3 (46.3–53.9)	50.0 (46.1–55.0)	0.36
Marital status (married), n (%)	95 (57.9)	11 (55.0)	61 (62.2)	23 (50.0)	0.37
Educational level (greater	36 (21.8)	5 (25.0)	17 (17.2)	14 (30.4)	0.19

than or equal to college level), n (%)					
Employment status (full-time), n (%)	38 (23.0)	12 (60.0)	22 (22.2)	4 (8.7)	0.00
Living status (living alone), n (%)	43 (26.4)	7 (35.0)	24 (24.5)	12 (26.7)	0.62

581 IQR, interquartile range; DAS28-ESR, Disease Activity Score (28 joint count)- erythrocyte sedimentation  
582 rate; mHAQ, modified Health Assessment Questionnaire; BMQ, Beliefs about Medicines Questionnaire;  
583 CES-D, Center for Epidemiological Studies Depression; BPI, Brief Pain Inventory; NRS, Numerical  
584 Rating Scale; SDS, Social Desirability Scale; SF-8, 8-item Short-Form Health Survey; PCS, physical  
585 component summary; MCS, mental component summary; MTX, methotrexate; MMAS-8, Morisky  
586 Medication Adherence Scale

587

588 **Table 2. Factors associated with MTX adherence using linear regression analysis (n=165)**

	Coef.	95% CI	p value
Age	0.02	0.00–0.03	0.03
Female	-0.09	-0.58–0.40	0.73
Disease duration	0.00	-0.00–0.00	0.41
RA activity (DAS28-ESR)	0.16	-0.03–0.35	0.09
Depression state (CES-D)	-0.26	-0.69–0.18	0.25
Belief about medicine (BMQ necessity-concern differential)	0.01	-0.07–0.09	0.86
Social desirability (SDS)	0.14	0.05–0.23	0.00
Educational level (more than or equal to college level or not)	0.36	-0.10–0.82	0.13
Employment status (full-time work or not)	-0.50	-0.95–0.05	0.03

589

590 MTX, methotrexate; RA, rheumatoid arthritis; DAS28-ESR, Disease Activity Score (28 joint

591 count)-erythrocyte sedimentation rate; BMQ, Beliefs about Medicines Questionnaire; CES-D, Center for

592 Epidemiological Studies Depression; SDS, Social Desirability Scale; Coef, regression coefficients; CI,

593 confidence interval

594

595

**Figure 1. Patient flow chart**

